Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:IOVA NASDAQ:MNPR NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$84.80+0.4%$80.58$62.60▼$99.50$1.93B0.44391,147 shs170,917 shsIOVAIovance Biotherapeutics$4.26+0.1%$3.85$1.67▼$5.63$1.91B0.7314.90 million shs8.14 million shsMNPRMonopar Therapeutics$94.97+8.3%$62.26$29.18▼$105.00$636.43M1.52209,578 shs90,686 shsRAPPRapport Therapeutics$40.69+1.6%$37.23$11.05▼$42.27$1.95B0.97345,031 shs244,530 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals0.00%+6.30%+7.63%+14.64%+29.01%IOVAIovance Biotherapeutics0.00%+8.67%+3.66%+28.01%+151.48%MNPRMonopar Therapeutics0.00%+29.50%+34.81%+64.53%+160.95%RAPPRapport Therapeutics0.00%+7.28%+1.42%+44.67%+250.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$84.80+0.4%$80.58$62.60▼$99.50$1.93B0.44391,147 shs170,917 shsIOVAIovance Biotherapeutics$4.26+0.1%$3.85$1.67▼$5.63$1.91B0.7314.90 million shs8.14 million shsMNPRMonopar Therapeutics$94.97+8.3%$62.26$29.18▼$105.00$636.43M1.52209,578 shs90,686 shsRAPPRapport Therapeutics$40.69+1.6%$37.23$11.05▼$42.27$1.95B0.97345,031 shs244,530 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals0.00%+6.30%+7.63%+14.64%+29.01%IOVAIovance Biotherapeutics0.00%+8.67%+3.66%+28.01%+151.48%MNPRMonopar Therapeutics0.00%+29.50%+34.81%+64.53%+160.95%RAPPRapport Therapeutics0.00%+7.28%+1.42%+44.67%+250.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 2.75Moderate Buy$107.3326.57% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.4398.09% UpsideMNPRMonopar Therapeutics 3.00Buy$107.6713.38% UpsideRAPPRapport Therapeutics 2.91Moderate Buy$57.8642.18% UpsideCurrent Analyst Ratings BreakdownLatest MNPR, ANIP, RAPP, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026MNPRMonopar Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/29/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$105.006/24/2026RAPPRapport Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$52.006/23/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026RAPPRapport Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/1/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/21/2026RAPPRapport Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $65.005/18/2026RAPPRapport Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00 ➝ $56.005/14/2026ANIPANI Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$883.37M2.18$9.96 per share8.51$24.03 per share3.53IOVAIovance Biotherapeutics$285.61M6.65N/AN/A$1.76 per share2.42MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$78.34M$3.9521.479.79N/A9.98%27.51%10.02%8/14/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)RAPPRapport Therapeutics-$111.48M-$2.60N/AN/AN/AN/A-24.78%-23.44%8/6/2026 (Estimated)Latest MNPR, ANIP, RAPP, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28$2.05+$0.77$1.28$207.63 million$237.46 million5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/7/2026Q1 2026RAPPRapport Therapeutics-$0.56-$0.42+$0.14-$0.42$7.50 million$20.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.063.122.52IOVAIovance BiotherapeuticsN/A3.603.15MNPRMonopar TherapeuticsN/A56.0456.04RAPPRapport TherapeuticsN/A27.0827.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%IOVAIovance Biotherapeutics77.03%MNPRMonopar Therapeutics1.83%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals8.10%IOVAIovance Biotherapeutics7.80%MNPRMonopar Therapeutics9.70%RAPPRapport Therapeutics12.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60022.75 million20.90 millionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableRAPPRapport TherapeuticsN/A47.83 million41.86 millionN/AMNPR, ANIP, RAPP, and IOVA HeadlinesRecent News About These CompaniesRapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 23, 2026 | americanbankingnews.comEversept Partners LP Sells 84,332 Shares of Rapport Therapeutics, Inc. $RAPPJune 18, 2026 | marketbeat.comRapport Therapeutics, Inc. $RAPP is Cormorant Asset Management LP's 5th Largest PositionJune 18, 2026 | marketbeat.comArtia Global Partners LP Has $4.20 Million Stock Position in Rapport Therapeutics, Inc. $RAPPJune 18, 2026 | marketbeat.comIs Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?June 16, 2026 | insidermonkey.comRapport Therapeutics, Inc. $RAPP Stock Position Decreased by Sofinnova Investments Inc.June 16, 2026 | marketbeat.comKennedy Capital Management LLC Takes $5.42 Million Position in Rapport Therapeutics, Inc. $RAPPJune 16, 2026 | marketbeat.comRapport Therapeutics Holds 2026 Annual Shareholder MeetingJune 10, 2026 | tipranks.comGoldman Sachs Group Inc. Buys 579,903 Shares of Rapport Therapeutics, Inc. $RAPPJune 10, 2026 | marketbeat.comRapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comIs Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?June 8, 2026 | finance.yahoo.comBTIG Raises its Price Target on Rapport Therapeutics (RAPP)June 6, 2026 | finance.yahoo.comRAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal EpilepsyJune 4, 2026 | tipranks.comRock Ventures L.P. Third Sells 18,572 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMay 29, 2026 | insidertrades.comRapport Therapeutics Inc RAPPMay 27, 2026 | morningstar.comMRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceMay 20, 2026 | globenewswire.comRapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTradingMay 19, 2026 | theglobeandmail.comBTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)May 17, 2026 | theglobeandmail.comRapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells $5,376,788.32 in StockMay 14, 2026 | insidertrades.comRock Ventures L.P. Third Sells 5,018 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMay 12, 2026 | insidertrades.comRapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure MarketMay 7, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026What IBM's $10-Billion Quantum Project Means For Smaller PlayersBy Nathan Reiff | June 3, 2026Washington’s Quantum Push Puts IBM and IonQ on the ThroneBy Jeffrey Neal Johnson | June 25, 2026MNPR, ANIP, RAPP, and IOVA Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$84.80 +0.30 (+0.36%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Iovance Biotherapeutics NASDAQ:IOVA$4.26 +0.01 (+0.12%) As of 03:42 PM Eastern This is a fair market value price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Monopar Therapeutics NASDAQ:MNPR$94.96 +7.29 (+8.31%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Rapport Therapeutics NASDAQ:RAPP$40.69 +0.63 (+1.58%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Is Apple’s Latest Plunge the Canary in the Coal Mine for Tech Stocks? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
